HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

One-Two Punch On Supplements From Former FDA Investigator, Harvard Researchers

This article was originally published in The Tan Sheet

Executive Summary

Jeff Novitzky, VP of athlete health and performance at Ultimate Fighting Championship, discusses violative supplements at a Dietary Supplement Caucus briefing for lawmakers and congressional staff. Harvard researchers roundly criticize the products' potential health benefits.

You may also be interested in...



Split Decision In UFC Athlete's Complaint About Steroid-Containing Supplements

Some clams in Ultimate Fighting Championship competitor Lyman Good's complaint against Vitamin Shoppe, Gaspari Nutrition, Hi-Tech Pharmaceuticals and Millennium Sport Technologies will stand. Good's counsel, however, made "threadbare" arguments to sustain other charges he alleged, a judge says in New York federal court.

UFC Fighter Hits Genkor Tribulus Supplement With SARMs Complaint

Former UFC heavyweight champ Joshua Barnett's lawsuit filed in California state court two weeks after his suspension from UFC bouts was lifted alleges that BioKor’s Genkor Tributestin 750 supplement he used contained an undeclared ingredient, ostarine, a selective androgen receptor modulator that is a "dangerous chemical that is not approved for human consumption under any circumstances."

USADA Builds Team To Change Supplement Law, Cites "Lax" Regulations

The U.S. Anti-Doping Agency leads an alliance seeking stronger enforcement against steroid-containing nutritional supplements, proposing legislative changes that could significantly burden FDA and supplement manufacturers, retailers and distributors

Related Content

Topics

UsernamePublicRestriction

Register

RS108880

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel